Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

August 24, 2020

Study Completion Date

December 31, 2025

Conditions
Uncomplicated Falciparum Malaria
Interventions
DRUG

Artemether-lumefantrine

Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.

DRUG

Dihydroartemisinin-piperaquine

Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.

Trial Locations (1)

Unknown

Tropical Diseases Research Centre, Ndola

All Listed Sponsors
collaborator

Tropical Diseases Research Centre

UNKNOWN

lead

Johns Hopkins Bloomberg School of Public Health

OTHER